Jaguar Health, Inc.
JAGX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | -0.01 |
| FCF Yield | -134.53% | -242.17% | -245.27% | -105.23% |
| EV / EBITDA | -3.51 | -4.14 | -4.01 | -2.28 |
| Quality | ||||
| ROIC | -19.73% | -21.14% | -22.35% | -17.71% |
| Gross Margin | 64.58% | 82.31% | 76.74% | 84.13% |
| Cash Conversion Ratio | 0.49 | 0.59 | 0.70 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.20% | 2.22% | 0.73% | -0.75% |
| Free Cash Flow Growth | 23.41% | 15.35% | 6.52% | -23.73% |
| Safety | ||||
| Net Debt / EBITDA | -3.12 | -3.80 | -3.68 | -1.81 |
| Interest Coverage | -1,206.33 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.10 | 0.05 | 0.05 | 0.05 |
| Cash Conversion Cycle | 222.03 | 740.29 | 672.83 | 859.68 |